IP Library Granted Patent US 11,788,121
Granted Patent B2
US 11,788,121 · App. 17/544,669 · Granted Oct 17, 2023

Methods, systems, and compositions for counting nucleic acid molecules

Inventors: Matthew Sekedat (Ann Arbor, MI); Jeffrey Buis (Ann Arbor, MI); Ronald David Beaubien (Jackson, MI); Sharat Singh (Rancho Santa Fe, CA); Jeff Perry (Ann Arbor, MI)
Assignee: Enumera Molecular, Inc.
C12Q1/6834C12Q2565/537
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,788,121
App. No.
17/544,669
Granted
Oct 17, 2023
Kind
B2
Abstract

Compositions and methods, systems, and kits for detecting and quantifying variations in numbers of molecules, particularly variations in gene dosage, e.g., due to gene duplication, or to variations from the normal euploid complement of chromosomes, e.g., trisomy of one or more chromosomes that are normally found in diploid pairs, without digital sequencing.

Claims (41)

1. A method for counting circularized nucleic acids on a solid support, comprising:

a) forming at least one complex comprising an oligonucleotide primer hybridized to a circularized nucleic acid, wherein the primer is bound to a surface on a solid support;

b) detecting formation of the at least one complex in a process comprising:

i) extending the primer in the complex in a rolling circle amplification (RCA) reaction to form RCA product, wherein forming the RCA product comprises extending the primer bound to the surface on the solid support on the circularized nucleic acid in a reaction mixture comprising at least 12% PEG, wherein the PEG has an average molecular weight between 400 and 800;

ii) hybridizing a plurality of labeled probes to the RCA product; and

iii) detecting hybridized labeled probe;

wherein hybridized labeled probe at a locus on the surface on the solid support is indicative of formation of a complex comprising an oligonucleotide primer hybridized to a circularized nucleic acid at that locus on the solid support.

2. The method of claim 1 , wherein the surface on the solid support comprises a silanized surface comprising glass.

3. The method of claim 1 , wherein the primer is bound directly to the surface on the solid support, and wherein:

i) the primer is covalently linked to the surface on the solid support; or

ii) the primer comprises a biotin moiety and the surface on the solid support comprises avidin or streptavidin.

4. The method of claim 1 , wherein the circularized nucleic acid is a circularized molecular inversion probe (MIP) provided by a method comprising:

i) hybridizing MIPS to a sample of nucleic acid molecules to generate at least one hybridized MIP;

ii) in a ligation reaction mixture, circularizing the at least one hybridized MIP to form the at least one circularized nucleic acid.

5. The method of claim 4 , wherein the sample of nucleic acid molecules comprises DNA from a sample from a subject.

6. The method of claim 5 , wherein the sample from a subject is a blood or blood product sample.

7. The method of claim 1 , wherein hybridizing labeled probes to the RCA product comprises forming the RCA product in a reaction mixture that further comprises more than 100 nM labeled probe.

8. The method of claim 1 , wherein a plurality of RCA products hybridized to labeled probes are immobilized on the surface of the solid support in a dispersal, wherein at least a portion of the plurality of the RCA products are individually detectable by detection of the hybridized labeled probes.

9. The method of claim 8 , wherein the dispersal of RCA products is irregular.

10. The method of claim 1 , wherein the at least one labeled probe comprises a fluorescent label, and wherein the detecting comprises detecting fluorescence.

11. The method of claim 10 , wherein detecting fluorescence comprises fluorescence microscopy.

12. The method of claim 8 , wherein the plurality of different RCA products are hybridized to labeled probes that all comprise the same label.

13. The method of claim 1 , comprising:

a) providing a silanized surface comprising reactive groups on the solid support;

b) forming labeled complexes at a plurality of loci on the silanized surface, each labeled complex comprising labeled probes hybridized to an RCA product; and

c) counting the labeled complexes on the silanized surface.

14. The method of claim 13 , wherein the reactive groups comprise one or more of:

acrylic groups; and

reactive amine groups.

15. The method of claim 13 , wherein the silanized surface comprises a glass surface treated with 3-aminopropyltriethoxysilane or 3-(trimethoxysilyl) propyl methacrylate.

16. A composition comprising:

a) a solid support with a silanized surface bound to a plurality of complexes, each complex comprising an oligonucleotide primer hybridized to a circularized nucleic acid, wherein the primer is bound to the solid support, wherein:

i) the primer is covalently linked to the silanized surface; or

ii) the primer comprises a biotin moiety and the silanized surface comprises avidin or streptavidin, and

b) a reaction mixture in contact with the plurality of complexes, the reaction mixture comprising a DNA polymerase and at least 12% PEG, wherein the PEG has an average molecular weight between 400 and 800.

17. The composition of claim 16 , wherein the reaction mixture further comprises labeled probe comprising a fluorescent label.

18. The composition of claim 16 , wherein the primers are bound to the solid support in an irregular dispersal.

19. The composition of claim 16 , wherein the PEG has an average molecular weight of 600.

20. The composition of claim 16 , wherein the composition comprises at least 16% (w:v) PEG.

21. The composition of claim 16 , wherein the composition comprises at least 18% (w:v) PEG.

22. The composition of claim 16 , wherein the composition comprises at least 20% (w:v) PEG.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: BIORA THERAPEUTICS, INC.
To: ENUMERA MOLECULAR, INC.
Reel/Frame 060092/0687 →
CHANGE OF NAME Recorded May 16, 2022
From: PROGENITY, INC.
To: BIORA THERAPEUTICS, INC.
Reel/Frame 060072/0817 →
Continuity (4)
Continuation 16373568 · Apr 2, 2019
Provisional Application 62660699 · Apr 20, 2018
Provisional Application 62651676 · Apr 2, 2018
Related Publication 20220090180A1 · Mar 24, 2022